Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Bexagliflozin in Moderate Hepatic Impairment
NCT03557658Phase 1Completed
- Sponsor
- Theracos, Inc.
- Start
- Jul 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bexagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Theracos, Inc. Primary endpoints: Maximum Observed Plasma Concentration, Time of Maximum Observed Plasma Concentration and 3 more. Started Jul 2018; status: completed.
02
Drugs
bexagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03557658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03557658.